Breaking News

Lilly, QIAGEN In Companion Diagnostics Pact

May 30, 2014

To develop DNA and RNA biomarker assays in common cancers

QIAGEN N.V. and Eli Lilly and Co. have entered a collaboration to develop assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. QIAGEN will use its multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.    
 
This is the companies’ fourth project. In 2011, QIAGEN and Lilly partnered to develop a companion diagnostic that evaluates a gene mutation, which plays a role in some blood cancers. In 2013, a third project involved creating a companion diagnostic to guide use of an undisclosed Lilly oncology compound.
 
"We are excited to add a new stage to our successful collaboration with Lilly, this time co-developing a broad panel of molecular assays covering a range of biomarkers with diverse nucleic acid analytes and modalities to guide the use of tailored therapies. We believe our technology can enhance Lilly's development of innovative therapies for the benefit of cancer patients," said Peer M. Schatz, chief executive officer of QIAGEN. “Our collaborations with Lilly are among more than 20 co-development and co-commercialization projects underway with leading pharmaceutical and biotechnology companies."
 
Richard B. Gaynor, M.D., senior vice president, Oncology-Clinical Product Development and Medical Affairs, of Lilly, said, "Certain applications in biomarker development for tailoring oncology therapeutics require the combined analysis of DNA and RNA, and this collaboration provides a multi-modal, multi-analyte solution that can process multiple sample types and biomarkers in a single test. We are pleased to work with QIAGEN on this novel platform to support our development programs."

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity